NovAliX and Inventiva form strategic alliance for nuclear
receptor drug targets
22 April 2013
Inventiva and NovAliX announced that they have entered into a
strategic alliance dedicated to the discovery of clinical
candidates, targeting nuclear receptors.
After several years of successful collaboration in the field of
nuclear receptors and a proven track record with three programs
having reached clinical stage, Inventiva and NovAliX are now
officially teaming up to establish a solid alliance to further
deliver on the therapeutic promises of the nuclear receptor target
Through this alliance, Inventiva and NovAliX offer pharmaceutical
and biotech companies a unique set of fully integrated nuclear
receptor drug discovery capabilities by combining their respective
in-depth expertise in structural biology, medicinal chemistry,
biology, DMPK, pharmacology and safety.
This alliance will leverage Inventiva’s and NovAliX’s diversified
proprietary libraries in combination with complementary screening
technologies (multiple biophysical techniques combined with
biochemical and bio-functional assays). For the first time,
pharmaceutical and biotech companies will be able to entrust their
entire nuclear receptor drug discovery program from target
validation to IND stage to one single experienced partner.
Pierre Broqua, CSO and co-founder of Inventiva, stated “This is a
great opportunity for pharmaceutical and biotech companies wishing
to engage in discovery collaborations to address this major,
therapeutically relevant, target class. Based on our unique
drug-discovery platform, proven track record in nuclear receptors,
and our experience in managing collaborations, I strongly believe in
our ability to again deliver innovative drug development candidates
to our partners”.
Denis Zeyer, CEO of NovAliX, stated, “Ten years ago we built the
company on the academic legacy of Pierre Chambon and Dino Moras,
world class scientists, who pioneered the field of structural
biology and nuclear receptors. We have turned that academic
excellence into promising pharmaceutical candidates and this
alliance is the opportunity to further extend that success”.